Osemitamab（TST001）是一种针对claudin-18.2的人源化单克隆抗体，由人鼠嵌合体TST001的γ-1链与κ链的二聚体构成，具有对NK细胞介导的肿瘤杀伤活性，可用于胃/胃食管结合部腺癌，PDAC和肺癌。

Fuzapladib (IS-741) (IS-741)是一种磷脂酶A2抑制剂，可以抑制细胞粘附分子Mac-1的表达。fuzpladib 阻断炎症细胞表面表达的粘附分子(integrin)的激活，阻止炎症细胞粘附血管内皮细胞和浸润组织，控制胰腺炎的恶化。

Gantofiban是一种糖蛋白 IIb/IIIa（GP IIb/IIIa）拮抗剂，可用于治疗心血管疾病，可用于研究血栓形成。

Cyclo(RADfK) 是选择性 α(v)β(3) 整合素配体，广泛用于新血管生成的研究、治疗和诊断。它是 cyclo (-RGDfK-) 的阴性对照， RGD 肽。 RGD 肽是细胞粘附的调节剂，并被整合素家族的几个成员识别。

6-O-Caffeoylarbutin(Robustaside B)是一种抗氧化的天然产物，能够诱导线粒体膜通透性转变，能够调节SIRT1/PI3K/AKT/NF-κB通路，改善小鼠的肝损伤和缺血性脑卒中症状。

α-Linolenic acid (ALA) is an essential fatty acid found in leafy green vegetables. ALA, as part of a low saturated fat diet, helps prevent cardiovascular disease. ALA decreases blood pressure, serum cholesterol levels, and platelet aggregation.

CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ), with an IC50 of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC50=4440 nM). CC-90005 can inhibit T cell activation by IL-2 expression[1]. CC-90005 shows the exquisite selectivity of CC-90005, with IC50s for all other family members of >3 μM[1].CC-90005 is a moderate inhibitor of both CYP2C9 (IC50=8 μM) and CYP2C19 (IC50=5.9 μM) in human liver microsomes[1].CC-90005 inhibits IL-2 expression in LRS_WBC human PBMCs, with an IC50 of 0.15 μM[1].CC-90005 (1-10 μM; 24 h) inhibits T cell proliferation in PBMCs by 51% at 1 μM and 88% at 3 μM[1]. CC-90005 (3-30 mg/kg; p.o. twice daily for 4 days) significantly reduces the popliteal lymph node (PLN) size in a model of chronic T cell activation[1].CC-90005 (100 mg/kg; a single p.o.) significantly inhibits plasma and spleen IL-2 release by 51 and 54%, respectively[1].CC-90005 exhibits reasonable oral bioavailability (66 and 46%) and Cmax (1.18 and 1

DOTA-cyclo(RGDfK) 是一种和DOTA类螯合剂多肽，由多肽交联剂DOTA和环状多肽RGDFK构成二聚体，优先靶向肿瘤细胞膜上表达的αvβ3整合素受体，可制备放射性核素偶联物（RDC）并用于癌症诊断和治疗。

6'-Sialyllactose Sodium Salt (6'-N-Acetylneuraminyl-D-lactose sodium salt)是一种存在于母乳中的低聚糖，对 LPS 诱导的 ALI 具有保护作用，通过抑制 STAT1 和 NF-κB 信号通路来减轻 LPS 诱导的肺损伤。